## Special Issue

## New Directions in the Treatment of Gynecological Cancers

### Message from the Guest Editors

The effective treatment of gynecological cancers is the rising problem globally. The introduction of new drugs such as bevacizumab, PARP inhibitors, or checkpoint inhibitors that target PD-1 or PD-L1 has changed treatment strategies while posing new challenges. The management of some of the side effects of these new drugs and the introduction of subsequent lines of treatment may be a problem. Finally, there are also unresolved issues around surgical and palliative treatment that must be addressed. For instance, more research is needed to identify successful strategies to prevent and screen for cancer, as well as on additional biomarkers that can predict response to planned therapy, on the management of side effects of treatment and on the improvement of quality of life, including through nutritional therapies. The scope of this Special Issue is to provide an overview of recent advances in the field of gynecological oncology and to set new research directions. Therefore, researchers in the field of gynecological cancer treatment are encouraged to submit an original article or review to this Special Issue (case reports and short reviews will not be accepted).

### **Guest Editors**

Dr. Marcin Mardas

Department of Oncology, Poznan University of Medical Science, Poznan, Poland

Prof. Dr. Janina Markowska

Department of Oncology, Poznań University of Medical Sciences, Szamarzewskiego 82/84, 60-569 Poznań, Poland

### Deadline for manuscript submissions

closed (20 October 2022)



# Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/93480

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/

jcm





# Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





### **About the Journal**

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

### **Editors-in-Chief**

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of Tokyo, Tokyo, Japan

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).